Overview

Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if ABX-EGF is safe and efficacious in patients with metastatic colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Panitumumab